Weight-based administration of dalteparin in obese patients

American Journal of Health-System Pharmacy

Volumn 60, Issue 7, 2003, Pages 683-687

  Smith, Jennifer ^a   Canton, E Michael ^b  

^a Costco Pharmacy ^*  (United States)

^b Sacred Heart Medical Center Eugene   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MALE; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; THROMBOSIS PREVENTION; UNSTABLE ANGINA PECTORIS;

EID: 0037528877     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.7.683     Document Type: Article

References (12)

1. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119:64S-94S.
2. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001; 21:218-34.
3. Laposata M, Green D, Van Cott EM et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998; 122:799-807.
4. Marci CD, Prager D. A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol. 1993; 99: 546-50.
5. Beers MH, Berkow R, Burs M, eds. The Merck manual of diagnosis and therapy. 17th ed. Rathway, NJ: Merck; 1999.
6. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996; 26 (suppl 2):24-38.
7. Hainer JW, Barrett JS, Assaid CA et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002; 87:817-23.
8. Leizorovicz A, Bara L, Samama MM et al. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 1993; 23 (suppl 1):89-98.
9. Kovacs MJ, Weir K, MacKinnon K et al. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res. 1998; 91:137-42.
10. Samama MM, Verhille C, Carchy L. Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery. Thromb Haemost. 1995; 73:977. Abstract.
11. Nieuwenhuis HK, Albada J, Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991; 78:2337-43.
12. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol. 2000; 56:293-7.